Old and new acetylcholinesterase inhibitors for Alzheimer’s disease
The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: To date, pharmacological treatment of Alzheimer's disease (AD) includes Acetylcholinesterase Inhibitors (AChEIs) for mild-to-moderate AD, and memantine for moderate-to-severe AD. AChEIs reversibly inhibit acetylcholinesterase (AChE), thus increasing the availability of acetylcholine in cholinergic synapses, enhancing cholinergic transmission. These drugs provide symptomatic short-term benefits, without clearly counteracting the progression of the disease. AREAS COVERED: On the wake of successful clinical trials which lead to the marketing of AChEIs donepezil, rivastigmine and galantamine, many compounds with AChEI properties have been developed and tested mainly in Phase I-II clinical trials in the last twenty years. Here, we review clinical trials initiated and interrupted, and those ongoing so far. EXPERT OPINION: Despite many clinical trials with novel AChEIs have been carried out after the registration of those currently used to treat mild to moderate AD, none so far has been successful in a Phase III trial and marketed. Alzheimer's disease is a complex multifactorial disorder, therefore therapy should likely address not only the cholinergic system but also additional neurotransmitters. Moreover, such treatments should be started in very mild phases of the disease, and preventive strategies addressed in elderly people.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Traditional AD drugs (Fig. 5) are categorized into two classes: AChEIs (tacrine (3), donepezil (4), rivastigmine (5), galantamine (6)) and NMDA receptor antagonists (memantine (7)).396”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [396]
Citations
Cites
Doody, R. S., Gavrilova, S. I., Sano, M., Thomas, R. G., Aisen, P. S., Bachurin, S. O., Seely, L., & Hung, D. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61074-0 · Cited by 460 · cited 1×
“Dimebon was safe, well tolerated, and showed significant benefits in ADAS-cog [9].”
BackgroundMedhurst, A. D., Atkins, A. R., Beresford, I. J., Brackenborough, K., Briggs, M. A., Calver, A. R., Cilia, J., Cluderay, J. E., Crook, B., Davis, J. B., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.120311 · Cited by 301 · cited 1×
“In mice and rats, inhibiting this receptor has been shown to enhance cholinergic signaling, reduce tau phosphorylation, and reverse behavioral deficits [22,23].”
BackgroundYang, G., Wang, Y., Tian, J., & Liu, J.-P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074916 · Cited by 241 · cited 2×
“their findings cautiously, due to the poor methodological quality of the trials included [7].”
BackgroundWeinreb, O., Amit, T., Bar-Am, O., & B.H. Youdim, M. (2012) · Current Drug Targets · doi:10.2174/138945012799499794 · Cited by 153 · cited 1×
“Finally, it possesses potent antiapoptotic and neuroprotective activities in vitro and in various neurodegenerative rat models (see [39] for review).”
BackgroundLin, C., Chen, P.-K., Chang, Y., Chuo, L.-J., Chen, Y.-S., Tsai, G. E., & Lane, H. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.08.010 · Cited by 143 · cited 1×
“D-amino acid oxidase inhibitor, gave promising results [55].”
BackgroundGrove, R., Harrington, C., Mahler, A., Beresford, I., Maruff, P., Lowy, M., Nicholls, A., Boardley, R., Berges, A., Nathan, P., et al. (2014) · Current Alzheimer Research · doi:10.2174/1567205010666131212110148 · Cited by 109
Huperzine A for Alzheimer's disease
Li, J., Wu, H. M., Zhou, R. L., Liu, G. J., & Dong, B. R. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005592.pub2 · Cited by 108
Lemes, L. F. N., Ramos, G. D. A., de Oliveira, A. S., da Silva, F. M. R., Couto, G. C., Boni, M. S., Guimarães, M. J. R., Souza, I. N. D. O., Bartolini, M., Andrisano, V., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.024 · Cited by 100 · cited 1×
“A number of novel compounds have been synthesized and studied from a pharmacological and biochemical point of view or in mouse and rat models, including novel tacrine-related cholinesterase inhibitors [45], novel 7-aminoalkyl-substituted flavonoid derivatives [46], racemic benzochromenopyrimidinimines [47], Schiff bas…”
BackgroundA Randomized Study of H3 Antagonist ABT-288 in Mild-To-Moderate Alzheimer's Dementia1
Haig, G. M., Pritchett, Y., Meier, A., Othman, A. A., Hall, C., Gault, L. M., & Lenz, R. A. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140291 · Cited by 71 · cited 1×
“cally inferior to placebo but no statistical differences were detected [25].”
BackgroundNathan, P. J., Boardley, R., Scott, N. E., Berges, A., Maruff, P. T., Sivananthan, T., Upton, N., Lowy, M. T., Nestor, P. J., & Lai, R. Y. K. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310030003 · Cited by 69 · cited 1×
“and had positive effects on tasks of attention and memory[17].”
Background
Research works printed but not linked: 2
- Birks J, 2006, Cochrane Database Syst Rev, 1, CD005593
- Abd Razik BM, 2016, Med Chem, 12
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Targeting Free Radicals in Oxidative Stress-Related Human Diseases
Poprac, P., Jomova, K., Simunkova, M., Kollar, V., Rhodes, C. J., & Valko, M. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.04.005 · Cited by 1,107
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimer’s disease
Thapa, P., Upadhyay, S. P., Suo, W. Z., Singh, V., Gurung, P., Lee, E. S., Sharma, R., & Sharma, M. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104681 · Cited by 166
“Extensive research on drug discovery and development has led to FDA-approved drugs which include cholinesterase inhibitors such as donepezil (DPZ) [30–32], rivastigmine (RIV) [33–35], galantamine [36, 37], and a partial N -methyl-D-aspartate (NMDA) antagonist, Memantine[38] (Figure 3) [39].”
BackgroundMoss, D. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103438 · Cited by 146
“The current AChE inhibitors are far from adequate to meet the demand for highly effective AD interventions [81] that are urgently needed to improve cognitive functions and/or take advantage of the recently recognized additional anti-neurodegenerative benefits [54–62].”
BackgroundCognitive Decline in Preclinical Alzheimer’s Disease: Amyloid-Beta versus Tauopathy
Huber, C. M., Yee, C., May, T., Dhanala, A., & Mitchell, C. S. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170490 · Cited by 131
In Vitro and in Vivo Biological Investigations of Camphene and Its Mechanism Insights: A Review
Hachlafi, N. E., Aanniz, T., Menyiy, N. E., Baaboua, A. E., Omari, N. E., Balahbib, A., Shariati, M. A., Zengin, G., Fikri-Benbrahim, K., & Bouyahya, A. (2021) · Food Reviews International · doi:10.1080/87559129.2021.1936007 · Cited by 150
Yang, T., Xiao, T., Sun, Q., & Wang, K. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2017.09.001 · Cited by 120
Abdul Manap, A. S., Wei Tan, A. C., Leong, W. H., Yin Chia, A. Y., Vijayabalan, S., Arya, A., Wong, E. H., Rizwan, F., Bindal, U., Koshy, S., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00206 · Cited by 110
Tohma, H., Altay, A., Köksal, E., Gören, A. C., & Gülçın, İ. (2019) · Journal of Food Measurement & Characterization · doi:10.1007/s11694-019-00077-9 · Cited by 124
“The evidence showed that the neurotransmitter acetylcholine (ACh) decreases due to either a decline in choline (Ch) by acetyl transferase activity or excess degradation of ACh by acetylcholinesterase [27].”
BackgroundYuan, B., Zhu, Q., Guo, N., Zheng, S.-J., Wang, Y., Wang, J., Xu, J., Liu, S., He, K. F., Hu, T., et al. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.7b05355 · Cited by 99
Toll-Like Receptor 4: A Promising Therapeutic Target for Alzheimer’s Disease
Wu, L., Xian, X., Xu, G., Tan, Z., Dong, F., Zhang, M., & Zhang, F. (2022) · Mediators of Inflammation · doi:10.1155/2022/7924199 · Cited by 107
“Acetylcholinesterase (AChE) is a hydrolytic enzyme that hydrolyses acetylcholine to choline and acetic acid [132, 133].”
BackgroundTahir, S., Ramzan, M. S., Hassan, A., Sadiq, A., Jan, M. S., Khan, F. A., Ullah, F., Ahmad, H., Bibi, M., Mahmood, T., et al. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.10.035 · Cited by 86
“8-chloro-11-(1-(4-chlorobenzyl) piperidin-4-ylidene)-6, 11-dihydro5H-benzo[5,6]cyclohepta [1, 2-b] pyridine (1b) 1b was synthesized according to general procedure by using 8 and 4-chlorobenzylchloride (22).”
MethodInfluentialPalanimuthu, D., Poon, R., Sahni, S., Anjum, R., Hibbs, D. E., Lin, H.-Y. J., Bernhardt, P. V., Kalinowski, D. S., & Richardson, D. R. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.021 · Cited by 83
Galvin, V. C., Yang, S. T., Paspalas, C. D., Yang, Y., Jin, L. E., Datta, D., Morozov, Y. M., Lightbourne, T. C., Lowet, A. S., Rakic, P., et al. (2020) · Neuron · doi:10.1016/j.neuron.2020.02.030 · Cited by 79
Satoh, A., & Iijima, K. M. (2019) · Brain Research · doi:10.1016/j.brainres.2017.12.027 · Cited by 68
Yan, Q., Wang, W., Weng, J., Zhang, Z., Yin, L., Yang, Q., Guo, F., Wang, X., Chen, F., & Yang, G. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1797240 · Cited by 75
“Numerous drugs have been designed and developed in the past several decades, including acetylcholinesterase inhibitors (AChEIs) (Galimberti & Scarpini, 2016) and cerebral blood flow and brain metabolism improver (Wu & Wen, 2016).”
BackgroundSarfraz, M., Sultana, N., Rashid, U., Akram, M. S., Sadiq, A., & Tariq, M. I. (2017) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2017.01.004 · Cited by 69
“and Ladostigil) and many more which are under preclinical and clinical trials [3, 6-7].”
BackgroundEl‐Sayed, N. A., Farag, A. E.-S., Ezzat, M. A. F., Akıncıoğlu, H., Gülçın, İ., & Abou‐Seri, S. M. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103312 · Cited by 68
“AChE levels remains unchanged in early stages of the disease while during progression of the disease, AChE levels were found to gradually decrease and at the same time BChE remains unaltered or increased in advanced AD [10,11].”
BackgroundÇakmak, R., Ay, B., Çınar, E., Başaran, E., Akkoç, S., Boğa, M., & Taş, E. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.136225 · Cited by 52
Mokhtari, Z., Baluchnejadmojarad, T., Nikbakht, F., Mansouri, M., & Roghani, M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.12.067 · Cited by 48
“In addition to degradation and dysfunction of cholinergic receptors, an inappropriate change in activity and level of acetylcholinesterase (AChE) is also strongly involved in cognitive deficits associated with AD and for this reason AChE inhibitors may be of benefit for management of mild to moderate AD [6].”
BackgroundZhan, G., Liu, J., Zhou, J., Sun, B., Aisa, H. A., & Yao, G. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.10.057 · Cited by 46
Chen, K., Wen, X., Wu, Z., Wang, L., Zhou, B., Li, Y., Jiang, Q., & Cong, W. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.344841 · Cited by 47
“Inhibiting AChE activity to alleviate acetylcholine deficiency is an effective anti-AD strategy (Galimberti and Scarpini, 2016; Jiang et al., 2017).”
BackgroundRen, J.-M., Zhang, S.-L., Wang, X., Guan, Z., & Qi, X. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11253 · Cited by 49
Biosynthesis and Biological Activities of Newly Discovered Amaryllidaceae Alkaloids
Ka, S., Koirala, M., Mérindol, N., & Desgagné‐Penix, I. (2020) · Molecules · doi:10.3390/molecules25214901 · Cited by 50
Zhang, C., Hu, L., Liu, D., Huang, J., & Lin, W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00760 · Cited by 42
“Acetylcholinesterase (AChE) is a hydrolase that hydrolyzes acetylcholine into acetic acid and choline (Anand and Singh, 2013; Galimberti and Scarpini, 2016).”
BackgroundPharmacological Interventions to Attenuate Alzheimer’s Disease Progression: The Story So Far
Bazzari, F. H., Abdallah, D. M., & El-Abhar, H. S. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190301111120 · Cited by 42
Cutillas, A., Carrasco, A., Martinez‐Gutierrez, R., Pérez‐Ruiz, T., & Tudela, J. (2018) · Plant Biosystems - An International Journal Dealing with all Aspects of Plant Biology · doi:10.1080/11263504.2018.1445129 · Cited by 53
“For its part, acetylcholinesterase (AChE) has a key role in neurotrans-mission, and, therefore, in aromatherapy, agronomic insecticides, war gases, tumour development, as well as Alzheimer’s disease (Galimberti and Scarpini 2016).”
Fronza, M. G., Baldinotti, R., Martins, M. C., Goldani, B. S., Dalberto, B. T., Kremer, F. S., Begnini, K. R., Pinto, L. D. S., Lenardao, E. J., Seixas, F. K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43532-9 · Cited by 41
Lim, X. Y., Tan, T. Y. C., Rosli, S. H. M., Sa’at, M. N. F., Ali, S. S., & Mohamed, A. F. S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245471 · Cited by 39
Chen, Y., Zhu, J., Mo, J., Yang, H., Jiang, X., Lin, H., Gu, K., Pei, Y., Wu, L., Tan, R. X., et al. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2017.1412314 · Cited by 39
“(E)-3-(4-chloro-3-nitrophenyl)-N-(6-((1,2,3,4-tetrahydroacridin-9yl)amino)hexyl)acrylamide (20).”
Benzimidazole-derived Compounds Designed for Different Targets of Alzheimer’s Disease
Gülcan, H. O., Mavideniz, A., Sahin, M. F., & Orhan, İ. E. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190124123208 · Cited by 35
Structural Bioinformatics Applied to Acetylcholinesterase Enzyme Inhibition
Reynoso-García, M. F., Nicolas, D., Tenorio-Barajas, A. Y., & Reyes‐Chaparro, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083781 · Cited by 40
“In this context, molecular docking has not only facilitated the identification of new compounds with therapeutic potential but also allowed for the structural optimization of existing drugs, improving their pharmacokinetic profile and reducing adverse effects [43].”
Fernandes, T. B., Cunha, M. R., Sakata, R. P., Cândido, T. M., Baby, A. R., Tavares, M. T., Barbosa, E. G., Almeida, W. P., & Parise‐Filho, R. (2017) · Archiv der Pharmazie · doi:10.1002/ardp.201700163 · Cited by 35
Lotfi, S., Rahmani, T., Hatami, M., Pouramiri, B., Kermani, E. T., Rezvannejad, E., Mortazavi, M., Hafshejani, S. F., Askari, N., Pourjamali, N., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104457 · Cited by 33
Lee, J. E., Song, H.-S., Park, M., Kim, S., Shim, B., & Kim, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020363 · Cited by 35
“Many researchers have used stem cell therapy [31], vaccine [32], and AChEIs [33] for AD therapy.”
BackgroundPhenothiazine-Tacrine Heterodimers: Pursuing Multitarget Directed Approach in Alzheimer’s Disease
Górecki, L., Uliassi, E., Bartolini, M., Janočková, J., Hrabinová, M., Hepnarová, V., Prchal, L., Múčková, Ľ., Pejchal, J., Karasová, J. Ž., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00184 · Cited by 31
Singh, S. P., & Gupta, D. K. (2017) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2017.04.002 · Cited by 33
“Further, the limited efficacies of different hAChE inhibitors, currently under clinical trials, have been recently reviewed by Zemek et al. (2014) and Galimberti and Scarpini (2016).”
Rani, A., Singh, A., Kaur, J., Singh, G., Bhatti, R., Gumede, N. J., Kisten, P., Singh, P., Sumanjit, & Kumar, V. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105053 · Cited by 31
The Amaryllidaceae alkaloids: an untapped source of acetylcholinesterase inhibitors
Berkov, S. H., Atanasova, M., GEORGIEV, B., Bastida, J., & Doytchinova, I. A. (2021) · Phytochemistry Reviews · doi:10.1007/s11101-021-09790-0 · Cited by 30
Soliman, A. M., El-wahab, H. A. A. A., Akıncıoğlu, H., Gülçın, İ., & Omar, F. A. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106916 · Cited by 30
Alfei, S., & Zuccari, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020844 · Cited by 29
Ye, C., Xu, R., Cao, Z., Song, Q., Yu, G., Shi, Y., Liu, Z., Liu, X., & Deng, Y. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104895 · Cited by 26
Chen, H., Wu, X., Gu, X., Zhou, Y., Ye, L., Zhang, K., Pan, H., Wang, J., Hua, W., Zhu, B., et al. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00396 · Cited by 26
“Previous studies have shown that AChE inhibitors could improve cognitive performance via elevating cholinergic signaling (Galimberti and Scarpini, 2016).”
BackgroundKadi, I., Eltayb, W. A., Boufissiou, A., Benaceur, F., Bouchareb, A., Soltan, W. B., Baladehi, M. H., Kheniche, A., & Abdalla, M. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.135562 · Cited by 26
Liu, Q., Wu, J., Li, F., Cai, P., Yang, X., Kong, L., & Wang, X. (2017) · MedChemComm · doi:10.1039/c7md00199a · Cited by 23
Azam, U., Naseer, M. M., & Rochais, C. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117277 · Cited by 24
Du, Z., Liu, C., Liu, Z., Song, H. L., Scott, P., Du, X., Ren, J., & Qu, X. (2022) · Chemical Science · doi:10.1039/d2sc05897a · Cited by 21
Zhu, X., Cai, L., Liu, J., Zhu, W., Cui, C., Ouyang, D., & Ye, J. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123409 · Cited by 21
Computational Studies on Acetylcholinesterase Inhibitors: From Biochemistry to Chemistry
Bagri, K., Kumar, A., Manisha, M., & Kumar, P. (2019) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666191224144346 · Cited by 21
Gould, R. W., Russell, J. K., Nedelcovych, M. T., Bubser, M., Blobaum, A. L., Bridges, T. M., NEWHOUSE, P. A., Lindsley, C. W., Conn, P. J., Nader, M. A., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00812-7 · Cited by 23
“While AChEIs produce modest therapeutic effects on cognitive impairments during the early stages of AD, these drugs are associated with dose-limiting adverse effects due to nonselective activation of central and peripheral muscarinic acetylcholine receptors (mAChRs) [15].”
BackgroundYu, H., Ding, Y., Wei, Y., Dyrba, M., Wang, D., Kang, X., Xu, W., Zhao, K., Liu, Y., & Initiative, A. D. N. (2023) · Human Brain Mapping · doi:10.1002/hbm.26512 · Cited by 22
“ACHE and KCNIP3, the two most significantly correlated genes, have demonstrated a strong association with AD (Anekonda et al., 2011; Galimberti & Scarpini, 2016).”
BackgroundThe next step of neurogenesis in the context of Alzheimer’s disease
Moradi, H. R., Hajali, V., Khaksar, Z., Vafaee, F., Forouzanfar, F., & Negah, S. S. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06520-9 · Cited by 20
Butyrylcholinesterase-inhibiting natural coumarin molecules as potential leads
Orhan, İ. E., Tosun, F., Şenol, F. S., Eren, G., Mıhoğlugil, F., Akalgan, D., & Miski, M. (2021) · Phytochemistry Letters · doi:10.1016/j.phytol.2021.05.001 · Cited by 19
Involvement of Nicotinic Receptors in Working Memory Function
Galvin, V. C., Arnsten, A. F. T., & Wang, M. (2020) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_142 · Cited by 59
Detarium microcarpum: A novel source of nutrition and medicine: A review
Hassanin, H. A. M., Koko, M. Y. F., Abdalla, M., Mu, W., & Jiang, B. (2018) · Food Chemistry · doi:10.1016/j.foodchem.2018.09.070 · Cited by 16
Rimkus, S. A., & Wassarman, D. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190821 · Cited by 17
Yi, L., Luo, M., Wang, M., Dong, Z., & Du, Y. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1288506 · Cited by 16
“Impairment of the cholinergic system has been noted to be a signi fi cant pathological feature of AD, and the inhibition of AChE activity serves as the foremost clinical approach to AD treatment (Galimberti and Scarpini, 2016).”
BackgroundDiscovery of a Novel Acetylcholinesterase Inhibitor by Fragment-Based Design and Virtual Screening
Stavrakov, G., Philipova, I., Lukarski, A., Atanasova, M., GEORGIEV, B., Atanasova, T., Konstantinov, S., & Doytchinova, I. A. (2021) · Molecules · doi:10.3390/molecules26072058 · Cited by 17
“Any attempt to increase the dose to achieve a better AChE inhibition results in an increase in drug toxicity and limits the clinical benefits [12].”
BackgroundGrcic, L., Leech, G., Kwan, K., & Storr, T. (2024) · Chemical Communications · doi:10.1039/d3cc05834d · Cited by 15
Zhang, H., Liu, Y., Zhang, L., Tian, Z., Zhang, H., & Jiang, H. (2024) · Journal of Separation Science · doi:10.1002/jssc.202400288 · Cited by 14
Combined Structure and Ligand-Based Design of Selective Acetylcholinesterase Inhibitors
Pérez‐Sánchez, H., den-Haan, H., Pérez-Garrido, A., Peña-García, J. J., Chakraborty, S., Orhan, İ. E., Şenol, F. S., & Villalgordo, J. M. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00463 · Cited by 15
Stage, E., Svaldi, D. O., Sokolow, S., Risacher, S. L., Marosi, K., Rotter, J. I., Saykin, A. J., Apostolova, L. G., & Initiative, A. D. N. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12168 · Cited by 14
Niu, S., Huang, J., Chen, S., Lin, H. Y.-H., Kuo, I., Wu, P.-Y., Chiu, Y., & Chang, J. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00043 · Cited by 13
“Many neurological diseases of in the elderly such as dementia (Galimberti and Scarpini, 2016), Parkinson’s disease (Pelosin et al., 2016) and cognitive impairment (Liu et al., 2017) have been reported to be caused by age-related cholinergic dysfunction.”
BackgroundSharma, R. K., Singh, M., Ghimeray, K., Juneja, P., Dev, G., Pulavarthi, S., Reddy, S. R., & Akundi, R. S. (2021) · Molecules · doi:10.3390/molecules26175319 · Cited by 13
“However, the usage of these inhibitors is associated with adverse gastrointestinal disturbances and only modest improvements in cognitive functions [6].”
BackgroundPohanka, M. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666201117111715 · Cited by 12
Russell, J. K., Ingram, S., Teal, L. B., Lindsley, C. W., & Jones, C. K. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00592 · Cited by 13
Vitamin B3-Based Biologically Active Compounds as Inhibitors of Human Cholinesterases
Zandona, A., Lihtar, G., Maraković, N., Miš, K., Bušić, V., Gašo-Sokač, D., Pirkmajer, S., & Katalinić, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218088 · Cited by 12
“This is important especially since a diminished level of ACh in the brain is one of the characteristics of AD, so drugs designed as AChE inhibitors prevent ACh from fast degradation and enable longer-lasting neuro signals [9,10].”
BackgroundApplication of Natural Products in Neurodegenerative Diseases by Intranasal Administration: A Review
Jin, Y., Ma, X., Liu, S., Zong, S., Cheng, Y., Zhang, H., Wang, C., & Li, Y. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050675 · Cited by 11
Potent therapeutic targets for treatment of Alzheimer's disease: Amyloid degrading enzymes
Choi, H. S., Kim, E., Choi, J. Y., Park, E., & Lee, H. J. (2021) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.12390 · Cited by 12
Wang, Y., Xia, J., Shen, M., Zhou, Y., Wu, Z., Shi, Y., Xu, J., Hou, L., Zhang, R., Qiu, Z., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00003 · Cited by 15
“This interventionmay temporarily alleviate symptoms, but rarely exerts long-term effects or slows the pathological process of AD (Pang et al., 1996; Galimberti and Scarpini, 2016).”
BackgroundRecart, V. M., Spohr, L., Soares, M. S. P., de Mattos, B. D. S., Bona, N. P., Pedra, N. S., Teixeira, F. C., Gamaro, G. D., Stefanello, F. M., & Spanevello, R. M. (2021) · International Journal of Developmental Neuroscience · doi:10.1002/jdn.10086 · Cited by 11
“AChE inhibitors have been used to increase synaptic levels of ACh in neurodegenerative diseases (Galimberti & Scarpini, 2016).”
MethodSie, Y.-Y., Chen, L., Li, C., Wang, C., Li, C.-J., Liu, D.-Z., Lee, M., Chen, L.-G., & Hou, W. (2023) · Antioxidants · doi:10.3390/antiox12122058 · Cited by 11
“One class is acetylcholinesterase (AChE) inhibitors, based on the cholinergic hypothesis [9], such as donepezil [11,12]; another includes N -methyl- D-aspartate receptor antagonists (or glutamate regulators) such as memantine [11,13]; and the third is amyloid-targeting monoclonal antibodies such as…”
BackgroundZeman, J., Vetchý, D., Pavloková, S., Franc, A., & Pitschmann, V. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.113004 · Cited by 9
Song, X., Wang, T., Guo, L., Jin, Y., Wang, J., Yin, G., Jiang, K., Wang, L., Huang, H., & Zeng, L. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/2804849 · Cited by 8
“In current clinical practice, the drugs of acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists are the mainstay for the treatment of AD [7, 8].”
BackgroundGodyń, J., Zaręba, P., Stary, D., Kaleta, M., Kuder, K., Latacz, G., Mogilski, S., Reiner‐Link, D., Frank, A., Doroż-Płonka, A., et al. (2022) · Molecules · doi:10.3390/molecules28010238 · Cited by 8
Formulating the Structural Aspects of Various Benzimidazole Cognates
Krishnendu, P. R., Koyiparambath, V. P., Bhaskar, V., Arjun, B., & Zachariah, S. M. (2021) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621666211201122752 · Cited by 7
Conley, A. C., Key, A. P. F., Blackford, J. U., Russell, J. K., Albert, K. M., Gong, X., Bubser, M., Rook, J. M., Conn, P. J., Lindsley, C. W., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01798-4 · Cited by 7
Andersson, C. D., Martínez, N., Zeller, D., Allgardsson, A., Koza, M. M., Frick, B., Ekström, F., Peters, J., & Linusson, A. (2018) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.8b05485 · Cited by 6
Lee, J., Ju, I. G., Lim, Y., Kim, J. H., Lee, S.-M., Choi, Y., Oh, M. S., Kim, J., & Kim, D. (2024) · Biomaterials Science · doi:10.1039/d4bm01368a · Cited by 6
Nie, Y., Zhou, L., Li, Y., Yang, W., Liu, Y., Yang, Z., Ma, X., Zhang, Y., Hong, P., & Zhang, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.941994 · Cited by 6
“The inhibition of brain AChE elevates ACh levels and hence may positively affect cognitive function (Scarpini et al., 2016).”
BackgroundSemi-synthetic studies of α-onocerin derivatives for cytotoxicity
Pongpamorn, P., Wan-erlor, S., Ruchirawat, S., & Thasana, N. (2017) · Phytochemistry Letters · doi:10.1016/j.phytol.2017.11.017 · Cited by 6
Shi, Y., Zhang, H., Cong, S., Zhu, X., Liu, Y., Li, J., Tang, K., Xue, R., Liu, X., Tan, Z., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118437 · Cited by 6
ABBV‐552 in patients with mild Alzheimer's disease: a randomized phase IIb trial
Lynch, S. Y., Jia, J., Miles, N., Boiser, J. C., Buhl, D. L., Graff, O. X., & Zadikoff, C. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70994 · Cited by 4
“4 Although AChEIs, often used to treat patients with mild to moderate AD, 5 have shown some efficacy in treating cognitive deficits, their efficacy lessens as cognitive deficits increase over time.”
Goel, K. K., Chahal, S., Kumar, D., Jaiswal, S., Nainwal, N., Singh, R. K., Mahajan, S., Rawat, P., Yadav, S., Fartyal, P., et al. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00461b · Cited by 4
Boyton, I., Rennie, C., Collins‐Praino, L. E., & Care, A. (2024) · ChemNanoMat · doi:10.1002/cnma.202400147 · Cited by 5
The Endocannabinoid System in Local and Systemic Inflammation
Kelly, M. E. M., Lehmann, C., & Zhou, J. (2017) · Colloquium Series on Integrated Systems Physiology From Molecule to Function · doi:10.4199/c00151ed1v01y201702isp074 · Cited by 4
Delirium Superimposed on Dementia in Perioperative Period and Intensive Care
Krzych, Ł. J., Rachfalska, N., & Putowski, Z. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103279 · Cited by 5
“There is no evidence that those medications alter the course of the underlying dementing process [85].”
BackgroundMasum, M. H. U., Lokman, S. M., Parvin, R., Rahman, M. S., Chowdhury, E. H., Chamonara, K., Chowdhury, S., Mahdeen, A. A., & Khatun, M. M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326219 · Cited by 4
“Cholinesterase inhibitors and NMDA receptor antagonists are two examples of current medications that provide merely short-term cognitive improvements and fail to reverse the progression of the disease [54–56].”
Liu, W., Zhao, Y., Liu, T., Wang, Y., Yin, D., Zou, S., Zou, C., Zhang, Z., Zhi, H., & Wang, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1650534 · Cited by 3
“It is currently the most widely approved drug for mild-to-moderate AD treatment (Galimberti and Scarpini, 2016; Oliveira Silva et al., 2024).”
Mateev, E., & Georgieva, M. (2023) · Pharmacia · doi:10.3897/pharmacia.70.e113014 · Cited by 3
Xie, Y., Hou, Y., Hu, M., Chen, H., Wang, H., Zhao, L., & Xu, J. (2025) · Biosensors · doi:10.3390/bios15020118 · Cited by 4
Recent Advances in the Quest for Treatment and Management of Alzheimer and Other Dementia
Tanwir, S. E., & Kumar, A. (2019) · Open Journal of Medicinal Chemistry · doi:10.4236/ojmc.2019.91001 · Cited by 5
Su, J., Wei, J., Zhang, B., Wang, X., Tang, L., Yuan, Y., Sun, X., Qi, S., Yang, J., Xue, Y., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108502 · Cited by 3
Ibrahim, R. R., Salama, A., Abouelatta, S. M., & Elhabak, M. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-22844-z · Cited by 2
“In AD patients, cognitive decline is linked with ACh deficiency 49 .”
Wang, S., Li, S., Sun, X., Chen, Y., Yan, R., Liu, Y., & Wang, Z. (2026) · Scientific Reports · doi:10.1038/s41598-026-38642-0 · Cited by 2
“HupA is an acetylcholinesterase inhibitor that is clinically used to treat neurological diseases related to cognitive impairment 34 .”
Electrochemical Biosensors with Butyrylcholinesterase. Period 2016-2022. A review
Pohanka, M. (2022) · International Journal of Electrochemical Science · doi:10.20964/2022.12.74 · Cited by 2
Lee, J. H., Song, H.-S., Park, M., Kim, S., Shim, B., & Kim, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19040996 · Cited by 3
“Many researchers have used stem cell therapy [31], vaccine [32], and AChEIs [33] for AD therapy.”
BackgroundChimgin from Ferula haussknechtii as AChE inhibitor and confirmation of the absolute configuration
Feyzi, N., Ebadi, A., & Dastan, D. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2294176 · Cited by 1
“Therefore, there is a need for new and effective AChEIs that have higher efficacy and fewer side effects (Galimberti & Scarpini, 2016).”
Dobria, A., Suarez, A. A., Whitmarsh‐Everiss, T., Pavlinov, I., Soliz, V., Hippman, R. S., Petersson, T., Petros, Z. A., & Aldrich, L. N. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00780 · Cited by 1
Metadata
- Authors
- Galimberti, D., & Scarpini, E.
- Affiliations
- University of Milan (IT)
- Corresponding author
- Galimberti, Daniela
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2016-08-05
- Volume
- 25
- Issue
- 10
- Pages
- 1181-1187
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2487848811
- Cited by
- 117
- References
- 27
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 7 · 2023: 11 · 2022: 8 · 2021: 18 · 2020: 14 · 2019: 11 · 2018: 11 · 2017: 14 · 2016: 1
- FWCI
- 10.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- acetylcholinesterase inhibitors, Alzheimer's disease, donepezil, rivastigmine, galantamine, memantine, cholinergic neurotransmission, acetylcholine, clinical trials, drug development, early treatment, multifactorial therapy
- MeSH terms
- Acetylcholine, Aged, Alzheimer Disease, Animals, Cholinesterase Inhibitors, Humans, Severity of Illness Index, Drug Design, Treatment Outcome, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.